ABP-671 is under clinical development by Jiangsu Atom Bioscience and Pharmaceutical and currently in Phase II for Hyperuricemia. According to GlobalData, Phase II drugs for Hyperuricemia have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ABP-671’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ABP-671 overview

ABP-671 is under development for the treatment of gout associated with hyperuricemia and other hyperuricemia related diseases. It is a small molecule. The drug candidate is administered through oral route. The drug candidate acts by targeting urate transporter 1 (URAT1).

Jiangsu Atom Bioscience and Pharmaceutical overview

Jiangsu Atom Bioscience and Pharmaceutical (New Element Pharmaceutical) is a biopharmaceutical company that discover, develops and commercializes drugs to treat solid tumors and metabolic diseases. The company’s pipeline products ABP-671, a human transport urate protein 1 (hURAT1) inhibitor targeting gout and hyperuricaemia; and ABP-6016 against fatty liver, non-alcoholic steatohepatitis (NASH). It is also investigating ABP-431 and its structural analogues are firs-in-class anti-tumor drugs for the treatment of anti-gastric cancer, bowel cancer and triple-negative breast cancer. New Element Pharmaceutical also provide clinical trial services in collaboration with contract research organization (CRO) and pharmaceutical companies. The company’s funding partner include Hangzhou Kaitai Capita Co Ltd, Zhongyu Capital and YouChoose Capital. New Element Pharmaceutical is headquartered in Zhenjiang, Jiangsu, China.

For a complete picture of ABP-671’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.